Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Pennington

Clinical Cardiac Electrophysiology Wilmington, DE Medical Doctor

NPI 1932102647 CMS profile 1215329

701 N Clayton St Ste 533A, Ste 104, Wilmington, DE 19805

Open in the dashboard

General payments

$6,989

291 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Pennington of Wilmington, DE is reported in the CMS Open Payments database as having received $6,989 across 291 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 26th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $724 18
2024 General $1,042 18
2023 General $654 32
2022 General $1,420 59
2021 General $1,240 79
2020 General $545 38
2019 General $1,365 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Pennington
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Joseph Pennington were reported at $724. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Joseph Pennington Clinical Cardiac Electrophysiology median Middle half National median
2019 $1,365 $2,361 $585–$8,260 $163
2020 $545 $993 $247–$4,351 $114
2021 $1,240 $1,185 $326–$4,739 $132
2022 $1,420 $2,073 $554–$6,789 $149
2023 $654 $2,568 $759–$8,159 $160
2024 $1,042 $2,557 $703–$7,403 $164
2025 $724 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $3,484 188 payments
  2. Biotronik Inc. $1,064 14 payments
  3. Boston Scientific Corporation $888 20 payments
  4. E.R. Squibb & Sons, L.L.C. $690 49 payments
  5. Respicardia, Inc. $462 1 payment
  6. AstraZeneca Pharmaceuticals LP $100 5 payments
  7. Medicomp Inc $54 1 payment
  8. Janssen Pharmaceuticals, Inc $44 2 payments
  9. Scpharmaceuticals Inc. $37 1 payment
  10. Cardiovascular Systems Inc. $23 1 payment
  11. Other $142 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,022 287 payments
  2. Travel and Lodging $792 2 payments
  3. Consulting Fee $175 2 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS $472 33 payments
  2. remede System $462 1 payment
  3. Ensite Cardiac Mapping System $276 17 payments
  4. EnSite Precision Cardiac Mapping System $272 33 payments
  5. Fortify Assura, Ellipse ICD $256 9 payments
  6. AMVIA EDGE $250 2 payments
  7. ENSITE PRECISION $242 18 payments
  8. GALLANT $223 4 payments
  9. VIGILANT $220 5 payments
  10. CAMZYOS $218 16 payments
  11. Other $3,525 152 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

1,668

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$528,741

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

34.1%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 179 $236,318
Xarelto Rivaroxaban Brand 122 $155,225
Multaq Dronedarone Hcl Brand 31 $47,812
Droxidopa Generic 15 $33,366
Repatha Sureclick Evolocumab Brand 20 $14,083
Flecainide Acetate Generic 218 $12,191
Sodium Chloride 0.9 % Sodium Chloride Brand 53 $4,687
Amiodarone Hcl Generic 116 $4,002
Lisdexamfetamine Dimesylate Generic 12 $3,548
Metoprolol Succinate Generic 156 $2,985

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$173,029

Medicare's payments for the services billed

Medicare patients

1,139

Average age 76

Services billed

3,241

584 women, 555 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 52%
Arthritis 52%
Ischemic heart disease 42%
Heart failure 37%
Diabetes 36%
Chronic kidney disease 36%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

291 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record